Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells

Xing, Xiaojing; Wang, Xuguang; Liu, Meichen; Guo, Qianxue; Wang, Hongyue

doi:10.1080/15384047.2023.2193114

Cited by 2 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, emerging evidence demonstrates that the pathogenesis of DLBCL is complicated and consistent with aberrant gene expression that affects cell growth ( 48 ), invasiveness ( 49 ), angiogenesis ( 50 ), and apoptosis ( 51 ). It is reasonable for us to believe that CISD2 may play a significant role in DLBCL.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

Zhang,

Lin,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundDiffuse large B-cell lymphoma (DLBCL) is the most common B-cell lymphoma in adults. CDGSH iron sulfur domain 2 (CISD2) is an iron–sulfur protein and plays a critical role of cell proliferation. The aberrant expression of CISD2 is associated with the progression of multiple cancers. However, its role in DLBCL remains unclear.MethodsThe differential expression of CISD2 was identified via public databases, and quantitative real-time PCR (qRT-PCR) and western blot were used to identifed the expression of CISD2. We estimated the impact of CISD2 on clinical prognosis using the Kaplan-Meier plotter. Meanwhile, the drug sensitivity of CISD2 was assessed using CellMiner database. The 100 CISD2-related genes from STRING obtained and analyzed using the LASSO Cox regression. A CISD2 related signature for risk model (CISD2Risk) was established. The PPI network of CISD2Risk was performed, and functional enrichment was conducted through the DAVID database. The impacts of CISD2Risk on clinical features were analyzed. ESTIMATE, CIBERSORT, and MCP-counter algorithm were used to identify CISD2Risk associated with immune infiltration. Subsequently, Univariate and multivariate Cox regression analysis were applied, and a prognostic nomogram, accompanied by a calibration curve, was constructed to predict 1-, 3-, and 5-years survival probabilities.ResultsCISD2 was upregulated in DLBCL patients comparing with normal controls via public datasets, similarly, CISD2 was highly expressed in DLBCL cell lines. Overexpression of CISD2 was associated with poor prognosis in DLBCL patients based on the GSE31312, the GSE32918, and GSE93984 datasets (P<0.05). Nine drugs was considered as a potential therapeutic agents for CISD2. By using the LASSO cox regression, twenty seven genes were identified to construct CISD2Risk, and biological functions of these genes might be involved in apoptosis and P53 signaling pathway. The high CISD2Risk value had a worse prognosis and therapeutic effect (P<0.05). The higher stromal score, immune score, and ESTIMATE score were associated with lowe CISD2Risk value, CISD2Risk was negatively correlated with several immune infiltrating cells (macrophages M0 and M1, CD8 T cells, CD4 naïve T cells, NK cell, etc) that might be correlated with better prognosis. Additionally, The high CISD2Risk was identified as an independent prognostic factor for DLBCL patients using both univariate and multivariate Cox regression. The nomogram produced accurate predictions and the calibration curves were in good agreement.ConclusionOur study demonstrates that high expression of CISD2 in DLBCL patients is associated with poor prognosis. We have successfully constructed and validated a good prognostic prediction and efficacy monitoring for CISD2Risk that included 27 genes. Meanwhile, CISD2Risk may be a promising evaluator for immune infiltration and serve as a reference for clinical decision-making in DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

Zhang,

Lin,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

FOXO3 suppresses lymphoma progression through promoting miR‐34b/HSPG2 axis

Tao,

Huang,

Zhou

et al. 2024

Int J Lab Hematology

View full text Add to dashboard Cite

BackgroundDiffuse large B‐cell lymphoma (DLBCL) is the most common type of lymphoma, which caused many patients to lose their precious lives. FOXO3 was a suppressor in various cancers, however, the role and mechanism of FOXO3 in DLBCL remain unclear.MethodsBioinformatics analysis was used to offer information FOXO3 expression and its expression for prognosis of DLBCL patients. The abundance of genes and proteins was evaluated using RT‐qPCR and western blot. Cell proliferation and apoptosis was detected by CCK‐8 and flow cytometry. The interactions among FOXO3, miR‐34b, and HSPG2 were predicted by TransmiR and Starbase and validated using dual luciferase reporter assay, ChIP assay, and RIP assay.ResultsOur findings revealed that FOXO3 expression was abnormally declined in DLBCL cells. FOXO3 upregulation restrained cell proliferation and promoted cell apoptosis of DLBCL cells, while miR‐34b inhibitor eliminated these influences. Similarly, miR‐34b mimic suppressed malignant behaviors of DLBCL cells, which were abolished by HSPG2 overexpression. Mechanically, FOXO3 induced miR‐34b expression through interacting with miR‐34b promoter and HSPG2 was a targeted gene of miR‐34b.ConclusionFOXO3 attenuated the capability of cell proliferation and promoted cell apoptosis rate of DLBCL cells through affecting miR‐34b/HSPG2 axis, therefore inhibiting DLBCL progression.

show abstract

Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells

Cited by 2 publications

References 42 publications

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

FOXO3 suppresses lymphoma progression through promoting miR‐34b/HSPG2 axis

Contact Info

Product

Resources

About